|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
40,450,000 |
Market
Cap: |
989.00(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.37 - $27.55 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
329,070 |
329,070 |
523,966 |
603,682 |
Total Sell Value |
$8,517,127 |
$8,517,127 |
$12,486,163 |
$13,833,432 |
Total People Sold |
5 |
5 |
6 |
7 |
Total Sell Transactions |
6 |
6 |
18 |
22 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Patel Sanj K |
CHAIRMAN & CEO |
|
2023-03-16 |
4 |
D |
$11.46 |
$22,106 |
D/D |
(1,929) |
27,036 |
|
- |
|
Patel Sanj K |
CHAIRMAN & CEO |
|
2023-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,569 |
28,965 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2023-01-15 |
4 |
A |
$9.56 |
$17,629 |
D/D |
1,844 |
10,008 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2023-01-15 |
4 |
A |
$9.56 |
$6,730 |
D/D |
704 |
8,118 |
|
- |
|
Quart Barry D |
|
|
2022-11-29 |
4 |
S |
$16.15 |
$354,638 |
D/D |
(21,959) |
0 |
|
33% |
|
Quart Barry D |
|
|
2022-11-29 |
4 |
OE |
$1.59 |
$34,915 |
D/D |
21,959 |
21,959 |
|
- |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-11-07 |
4 |
AS |
$15.18 |
$430,459 |
D/D |
(28,357) |
36,335 |
|
-26% |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-11-07 |
4 |
OE |
$1.86 |
$52,744 |
D/D |
28,357 |
64,692 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-10-04 |
4 |
D |
$14.23 |
$740 |
D/D |
(52) |
7,414 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
175 |
7,466 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-09-02 |
4 |
D |
$11.44 |
$6,258 |
D/D |
(547) |
7,671 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,861 |
8,218 |
|
- |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-09-02 |
4 |
D |
$11.44 |
$5,800 |
D/D |
(507) |
36,335 |
|
- |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,725 |
36,842 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-09-02 |
4 |
D |
$11.44 |
$2,608 |
D/D |
(228) |
7,291 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
775 |
7,519 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2022-09-02 |
4 |
D |
$11.44 |
$6,441 |
D/D |
(563) |
8,164 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
995 |
8,727 |
|
- |
|
Patel Sanj K |
CHAIRMAN & CEO |
|
2022-09-02 |
4 |
D |
$11.44 |
$22,068 |
D/D |
(1,929) |
22,396 |
|
- |
|
Patel Sanj K |
CHAIRMAN & CEO |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,569 |
24,325 |
|
- |
|
Tessari Eben |
CHIEF OPERATING OFFICER |
|
2022-09-02 |
4 |
D |
$11.44 |
$6,601 |
D/D |
(577) |
114,648 |
|
- |
|
Tessari Eben |
CHIEF OPERATING OFFICER |
|
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,964 |
115,225 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-07-15 |
4 |
A |
$9.56 |
$6,721 |
D/D |
703 |
6,744 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2022-07-15 |
4 |
A |
$9.56 |
$3,442 |
D/D |
360 |
7,732 |
|
- |
|
Tessari Eben |
CHIEF OPERATING OFFICER |
|
2022-07-15 |
4 |
A |
$9.56 |
$10,019 |
D/D |
1,048 |
113,261 |
|
- |
|
241 Records found
|
|
Page 6 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|